Xiangya Institute of Medical Laboratory of Central South University (CSU) was developed and founded on the basis of Institute of Clinical Pharmacology and Institute of Genetic Pharmacology of CSU. After decades of struggle by Academician Zhou Honghao's team, it now has fourteen national and provincial technical platforms, such as the "National Technological Innovation Service Platform for Pharmacogenomic Applications", which can provide strong technical support for the smooth development of the Laboratory's programs. The laboratory has more than 2000 square meters of professional laboratories, special clinical pathology, clinical immunology, clinical gene amplification laboratory, clinical biochemistry, clinical microbiology, TDM laboratory and other specialized laboratories, and is equipped with advanced instruments and equipment. The Laboratory is set up in strict accordance with the "Basic Standards for Medical Testing Laboratories" issued by the Ministry of Health of the People's Republic of China, and has an advanced management team, a professional technical team, an experienced marketing and sales team, an enthusiastic and sincere customer service team, as well as domestic and foreign authoritative experts .
1)The National Technological Innovation Service Platform for Pharmacogenomic Applications
Approved by the Ministry of Science and Technology of the People's Republic of China in 2010, the platform integrates high-quality resources of talents, technology, equipment and information in the field of pharmacogenomic research, and provides public ****services such as individualized medical genetic testing, design of medication plans, information, standards and intellectual property rights for new drug development enterprises and medical institutions; industry, academia and research institutes can jointly carry out new drug research and development, clinical individual testing, and clinical individual testing. Jointly carry out the research and development of new drugs and individualized safe and rational use of drugs in clinics; industrialize and engineer existing drug genome-related research results; and accelerate the promotion of advanced and applicable technologies and new products to pharmaceutical enterprises and clinical medical institutions.
2)National Science and Technology Major Project - Key Technology Platform for Drug Safety Evaluation
The National Science and Technology Major Project has funded the establishment of a research platform for the study of Chinese drug metabolizing enzyme gene polymorphisms and their functional differences, and the establishment of a database on the distribution of drug metabolizing enzyme gene polymorphisms, enzyme activities and gene polymorphism detection technology, which will provide technical support for the screening of patients with drug-specific reactions and the safe use of drugs in the clinic. Provide technical support for the screening of patients with drug-specific reactions and the safe use of drugs in the clinic.
3)863 Key Project "Genome-wide Association Analysis and Pharmacogenomics Research of Major Diseases" Research Platform
Taking common major diseases that threaten people's health as a breakthrough, we will expound the genetic mechanism of disease causation, the genetic polymorphisms of genes related to drug genomics, through genome-wide association analysis and pharmacogenomics research. Through genome-wide association analysis and pharmacogenomics research, we will expound the genetic mechanism of disease causation, the interrelationship between genes polymorphisms related to genomics and the efficacy and safety of drugs, and discover new genetic markers and early warning targets for drugs and diseases, so as to provide theoretical basis, technical support, and talent reserves for the diagnosis, prevention, and safe and effective use of drugs for the Chinese population of complex and frequent major diseases.
4)Ministry of Education Engineering Research Center for Pharmacogenomic Application Technology
Established in 2007 by the Ministry of Education, the Center is a world-advanced engineering research center for pharmacogenomic application technology with comprehensive development and research functions. It is dedicated to the research and development of gene chips for individualized medication for nine major diseases, including hypertension, diabetes, mental illness, malignant tumors, ulcer disease, hyperlipidemia, etc., and builds production bases in compliance with GMP requirements, as well as special software and products with independent intellectual property rights. We will popularize the theoretical knowledge of individualized medication and promote the gene testing products for individualized drug therapy, so as to realize the safe and rational use of medication by the people; we will cooperate with the pharmaceutical companies to develop new medicines matching the results of gene testing for individualized drug therapy.
5)China Medical Board-CUNY Genetic Pharmacology Asian Model Laboratory
In 1999, China Medical Board (CMB) and the Genetic Pharmacology Laboratory of the University of Central South (UNCSS)**** established the Laboratory. Adopting the operation mechanism of CMB and Zhongnan University*** with the same investment*** to build the Genetic Pharmacology Laboratory.
The CMB Asian Model Laboratory of Genetic Pharmacology is the Asian Center of Genetic Pharmacology, aiming to promote the development of genetic pharmacology disciplines in the whole of Asia, and cultivate specialists in genetic pharmacology for the countries in Asia and other countries.
6)Asian Center for Genetic Pharmacology Advocacy International (PGENI)
Established in 2009 by the U.S. National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation***, the Center is headquartered at the Center for Individualized Pharmacotherapeutics and Pharmacogenomics at the University of North Carolina School of Medicine. The Institute of Clinical Pharmacology of Central South University is the only center of PGENI in East Asia, with the participation of 104 countries around the world and the establishment of seven centers around the globe. It aims to fund the cause of safe and individualized medication use in multi-ethnic populations around the world, and to integrate pharmacogenomic information into national public **** health and pharmacovigilance management decisions.
7)State Food and Drug Administration National Drug Clinical Research Base
The National Drug Clinical Research Base, which was certified by the State Food and Drug Administration (SFDA) in 2005, is a national center for phase I clinical trials of new drugs, clinical pharmacokinetic studies of new drugs and their technical consulting and services, data management and statistical analysis, as well as pharmacogenomics-based ((genetic) pharmacokinetic studies. Genetic) pharmacokinetic research of the national authoritative base.
8)National Training Center for Clinical Pharmacology of the Ministry of Health
Established in the early 1980s, it is the first batch of National Training Center for Clinical Pharmacology set up in China, and so far it has held 26 training courses nationwide, sending more than 3,000 high-level talents of drug clinical trials and drug clinical research to the country, aiming to popularize the standardization of drug research and the individualization of clinical drug use. The aim is to popularize the standardization of drug research and the individualization of clinical drug use.
9)Hunan Provincial Individualized Medication Consultation and Guidance Center
The Hunan Provincial Department of Health approved the establishment of the Center in June 2004, with 11 experts. By the Institute of Clinical Pharmacology of Central South University and Xiangya Third Hospital of Central South University *** with the formation of the first provincial-level individualized drug therapy consultation and guidance center. The center applies the research results of genetic pharmacology and pharmacogenomics, which have significant influence in the international arena, to individualized drug therapy and guides the clinical use of medication, providing services to improve the level of rational use of medication in the country and the safety of clinical use of medication.
10)Hunan Key Laboratory of Genetic Pharmacology
In February 2010, it was officially accepted and approved for construction by Hunan Provincial Science and Technology Department, and it is a research base of individualized medicine, a training base for senior professionals and a radiation base for the transformation of high-tech achievements with an important impact on the international scene. It has obvious advantages and characteristics in the direction of research on genetic variation and susceptibility to major diseases and the mechanism of their differences in response to drugs, and research on the basic and clinical application of genetic pharmacology of traditional Chinese medicine and natural drugs.
11)Hunan Provincial Biochip Industry Technology Innovation Strategic Alliance Technology Innovation Platform
May 2010 by the Hunan Provincial Department of Science and Technology formally approved the establishment of the key support for the production, learning and research technology innovation platform. By the province, led by the Institute of Clinical Pharmacology of Central South University in the field of biochip technology research, product development and industrialization of universities, enterprises, research institutes and medical institutions with a better basis for the joint formation. The main task of the alliance is to develop biochips for individualized gene diagnosis and individualized gene-targeted therapy. The development of this type of chip will greatly promote the development of individualized medical care in China.
12)Transgenic Cell Research Platform for In Vitro Screening of Drugs at Central South University
The National Special Project on Drug Safety Evaluation for the Creation of New Drugs has funded the establishment of the most authoritative recombinant cell platform for the stable expression of drug metabolizing enzymes (SNPs), which can be used for the determination and comparison of the differences in pharmacokinetics among different SNPs in vitro, and can be applied to innovative drugs. This platform can be used to determine and compare the pharmacokinetic differences between different SNPs in vitro, which can be applied to the screening and prediction of preclinical metabolism properties of innovative drugs or new drug lead compounds, and provide a scientific basis for the evaluation of potential drug safety in the clinic.
13) Genetic Drug Metabolism Kinetics (GDK) Drug Analysis and Detection Technology Platform of Central South University
The national-level GDK drug analysis and detection technology platform has the most advanced in vitro and in vivo drug concentration monitoring and analysis instruments in China, and the first-class Therapeutic Drug Monitoring (TDM) technology and analysis team based on the PhDs with rich experience in drug analysis in China. The strength of TDM technology is the first class in China.
14) Genetic Pharmacology and Pharmacogenomics Information Platform of Central South University
The first information search platform for the safe and rational use of medication in the Chinese population, which promotes the development of healthcare in China, provides a useful information base of Chinese ethnicity for the world's biological resources, and serves as a platform for the information resources for the translational application of pharmacogenomics.